HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV Prevention

Susan H. Eshleman(Johns Hopkins University), Richard Clark(Wellcome Sanger Institute), Myron S. Cohen(University of North Carolina at Chapel Hill), Beatriz Grinsztejn(Fundação Oswaldo Cruz), Sheila A. Peel(Henry M. Jackson Foundation), Estelle Piwowar‐Manning(Johns Hopkins University), Marty St. Clair(Coe College), Jeanne Marrazzo(St. Vincent's Birmingham), John W. Mellors(Textron Systems (United Kingdom)), Michael Seisa(LabCorp (United States)), Keren Middelkoop(Desmond Tutu HIV Foundation), William A. Meyer(Quest Diagnostics (United States)), Raphael J. Landovitz(APLA Health), Marybeth McCauley(Family Health International 360), James F. Rooney(Gilead Sciences (United States)), Elias K. Halvas(University of Pittsburgh), Ryan Kofron(APLA Health), Mark A. Marzinke(Family Health International 360), Eric S. Daar(UCLA Medical Center), Brett Hanscom(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Carole L. Wallis, Alex R. Rinehart, Zhe Wang(Southern Medical University), Yolanda Lie, Juan Hinojosa(Asociación para la Conservación de la Cuenca Amazónica), Robinson Cabello(Asociación Civil Impacta Salud y Educación), Jessica M. Fogel(Johns Hopkins University), Aida Asmelash(Family Health International 360), Adeola Adeyeye(National Institutes of Health)
The Journal of Infectious Diseases
October 14, 2022
Cited by 37


Related Papers